Introduction
Ovarian cancer is the seventh most common cancer diagnosis among women worldwide and the fifth most common cancer diagnosis among women in higher-resource regions [1] . The International Federation of Gynecology and Obstetrics (FIGO) staging classification was revised in 1988 [2] , and several subsequent scientific developments have challenged traditional concepts in ovarian cancer. The FIGO Committee on Gynecologic Oncology revised this classification in 2013 on the basis of these scientific developments in order to improve its utility and reproducibility [3] . Herein, we review the principal concepts of the revision and show some magnetic resonance imaging (MRI) and computed tomography (CT) examples for each disease stage.
Tumor types of ovarian cancer
Many histological types of malignant tumors arise from the ovaries, although approximately 90 % of malignant ovarian tumors are of epithelial origin. These tumors are classified into five major subtypes: high-grade serous carcinoma (HGSC, 70 %), low-grade serous carcinoma (LGSC, 5 %), clear-cell carcinoma (CCC, 10 %), endometrioid carcinoma (EC, 10 %), and mucinous carcinoma (MC, 3 %) [3, 4] . Although the FIGO committee chose for simplicity a flexible staging system shared by all tumor types, a description of each histological subtype is required in the revised version.
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immunohistochemical and molecular genetic analyses [5] [6] [7] [8] [9] . LSGC ( Fig. 1) and HGSC ( Fig. 2) are fundamentally different tumor types and even act as different diseases.
LGSCs are thought to develop through a stepwise process from benign serous cystadenomas/adenofibromas to serous borderline tumors and ultimately to LGSCs, are promoted by KRAS and BRAF mutations and are unrelated to TP53 and BRCA abnormalities [5] [6] [7] . It has been presumed that the precursors of serous cystadenomas/adenofibromas in this low-grade ovarian pathway are ovarian surface epithelial inclusion cysts [5, 6] .
In contrast, HGSCs are considered to be de novo promoted by TP53 and BRCA abnormalities. In HGSCs, early loss of TP53 function followed by BRCA function loss leads to deficiency in homologous recombination repair of double-strand DNA (dsDNA) breaks. Subsequent events cause global changes in the gene that facilitates tumor evolution (Fig. 3) [5] [6] [7] [8] [9] .
Definitiions of imaging findings of HGSC and LGSC have not yet been established. Serous borderline tumor, a precursor of LGSC, has been reported to appear as hyperintense papillary architecture with hypointense internal branching pattern on T2-weighted MRI [10, 11] , and LGSC sometimes retains these characteristics. In contrast, HGSC is often seen proliferating in a monotonous manner forming a homogeneous solid adnexal masses [12] with carcinomatous peritonitis.
An interpretation of the STIC theory
Recently, the serous tubal intraepithelial carcinoma (STIC) theory has become widely accepted, and it may be an origin of HGSCs of the ovary and peritoneum [5] [6] [7] [8] [9] . Most ovarian cancer, especially HGSC, appear with extensive peritoneal dissemination and is often difficult to identify its origin. STIC develops into an invasive HGSC with rapid LGSC are considered to arise from serous borderline tumors in the stepwise process and are promoted by KRAS and BRAF mutations. HGSC are considered to be de novo cancers promoted by TP53 and BRCA abnormalities tumor growth and implants early onto the ovary or peritoneum. In the STIC theory, most HGSCs are believed to be of STIC origin.
The fimbria of the fallopian tube is normally in intimate contact with the ovarian surface at the time of ovulation. It is conceivable that when the ovarian surface epithelium is disrupted, normal tubal epithelial cells from the fimbria may be dislodged and implanted on the ovarian surface to form an inclusion cyst. Exfoliation of malignant cells from an STIC implant on the ovarian surface results in the development of an HGSC of the ovary (Fig. 4) [6] .
According to this theory, there is no longer a reason for classifying HGSCs into ovarian, tubal, or peritoneal origin. Therefore, staging criteria of cancers of the ovary, fallopian tube, and peritoneum have been unified. STICs are often found in risk-reducing salpingo-oophorectomy specimens in BRCA-positive patients. In addition, TP53 mutations in both HGSC and STIC indicate a clonal relationship; HGSC shows similar immunoreactivity and secretory differentiation to that of STIC. These factors suggest that STIC is a precursor lesion of HGSC, and a distal fallopian tube is an important site for initiation of HGSC [5] [6] [7] [8] [9] .
HGSC often appears as massive ascites, omental caking, peritoneal nodules, or enhancement, and these findings are dominant imaging features of carcinomatous peritonitis [13] . Before STIC theory was widely recognized, these diseases were known as Müllerian carcinomas. Müllerian carcinoma is defined as a malignant epithelial tumor of Mül-lerian duct origin, including ovaries, fallopian tubes, and peritoneum. Extensive peritoneal carcinomatosis may also originate from extragenital organs, such as stomach, colon, or breast. Therefore, radiologists must correctly differentiate metastatic ovarian tumors from HGSC.
Revised FIGO staging criteria and key changes
We compared the revised FIGO staging classification for cancer of the ovary, fallopian tube, and peritoneum (2013) and FIGO staging classification of the ovary (1988) [2] ( Table 1) .
Stage I
Stage I disease is confined to ovaries or fallopian tubes and peritoneal fluid/washings. There is no longer a need to distinguish cancers of ovarian origin from those of fallopian tube origin in stage I disease. However, the staging classification is almost the same as the former version of each ovarian and fallopian tube cancer. Tumors limited to one ovary or one fallopian tube are classified as stage IA (Fig. 5) . Tumors limited to both ovaries or fallopian tubes are classified as stage IB (Fig. 6 ), which is relatively uncommon, accounting for only 1-5 % of stage I cases [14, 15] . Tumor ruptures or those with surface involvement by tumor cells are classified as stage IC (Fig. 7) . Microscopic spread of the tumor beyond adnexa is subdivided into stage IC1, IC2, or IC3 by its cause (IC1, surgical spill; IC2, capsule ruptured before surgery or tumor on ovarian or fallopian tube surface; IC3, malignant cells in ascites or peritoneal washings). Therefore, the disease is diagnosed as stage IC only when apparent rupture of the tumor capsule is seen without nodular implants on the surface of the peritoneum or pelvic organs.
Stage II
Diseases limited to the pelvis are classified as stage II, regardless of whether the mass originates from ovaries or fallopian tubes. Primary peritoneal cancer is classified as stage II or greater. The primary site (i.e., ovary, fallopian tube, peritoneum) should be designated where possible. In some cases, it may not be possible to delineate the primary site clearly; such cases should be listed as undesignated. Extension and/or implants to the uterus and/or fallopian tubes and/or ovaries are subclassified as stage IIA (Fig. 8) . Extension to other pelvic organs, such as colon or bladder, is subclassified as IIB (Fig. 9) . Stage II disease only involves the peritoneum within the pelvic brim, whereas stage III disease can involve anywhere beyond the pelvic brim (Figs. 10, 11) ; there is a clear difference in terms of survival between these two diseases [3] .
Stage III
Tumor spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes is classified (Fig. 12) and no longer as stage IIIC because patients with lymph node involvement without peritoneal involvement have better prognosis [16] [17] [18] [19] [20] [21] . Less than 10 % of ovarian carcinomas extend beyond the pelvis with exclusively retroperitoneal lymph node involvement [3] . Because lymphatic drainage of the ovary follows its venous supply by draining through the suspensory ligament to para-aortic lymph nodes and through the broad ligament to iliac chains, regional lymph nodes of ovarian/tubal/peritoneal carcinomas include obturator, internal, external, and common iliac nodes and para-aortic nodes below the renal hilum. On CT or MRI, lymph nodes with a short-axis diameter >1 cm or clusters of smaller lymph nodes are considered to be metastases [22, 23] . On [ 18 F]-fluorodeoxyglucose positron emission tomography (FDG-PET), diagnosis of metastatic lymph nodes is based on the presence of focal increased uptake of the tracer regardless of node size. The accuracy of detecting lymph node metastasis is reported to be higher in FDG-PET and FDG-PET/CT than in CT or MRI [15, 24, 25] . Sensitivity, specificity, and overall accuracy of PET or PET/CT were reported to be 73.2, 96.7, and 90.32 % and of CT were 42.6, 95.0, and 19.87 %; those of MRI were 54.7, 88.3, and 12.38 %, respectively [24] .
Microscopic extrapelvic peritoneal involvement is classified as stage IIIA2. It may appear on CT or MRI as massive ascites without implants. Macroscopic peritoneal metastasis beyond the pelvis of ≤2 cm in greatest dimension is classified as stage IIIB (Fig. 10) ; those >2 cm in greatest dimension are classified as stage IIIC (Fig. 11) . This is the same as the former staging classification. Tumor extension to capsules of the liver and spleen without parenchymal involvement of either organ is classified as stage IIIC and not IVB. HGSCs are often present in stage III, especially in stage IIIC (84 %) [5] , and these tumors typically spread along peritoneal surfaces: omentum, bowel, mesentery, paracolic gutters, diaphragm, and serosal surfaces of liver and spleen. Among patients with stage IIIC or IV, survival after neoadjuvant chemotherapy followed by debulking surgery has been reported to have a similar survival rate as that after primary debulking surgery followed by chemotherapy [26] .
Complete resection of all macroscopic disease at primary debulking surgery is the single most important independent prognostic factor, so radiologists should report details of all macroscopic peritoneal metastasis. Guidelines established by the European Society of Urogenital Radiology classify disease involving the following regions as being unresectable: retroperitoneal presacral disease, lymph node enlargement above the renal hilum, abdominal wall invasion, subcapsular liver metastases, and implants >2 cm in diameter at diaphragm, lesser sac, porta hepatis, intersegmental fissure, gall bladder fossa, gastrosplenic, gastrohepatic ligament, and small bowel mesentery [22] .
Stage IV
Generally, unresectable diseases-other than peritoneal metastasis and retroperitoneal lymph node metastasis-are designated as being stage IV. Stage IV disease, with malignant pleural effusion of positive cytology (Fig. 13) , is subdivided into stage IVA and, with distant metastasis, into stage IVB (Fig. 14) , which includes lymph node metastasis outside abdominal cavity: specifically, inguinal, supraclavicular, and cardiophrenic-angle lymph node metastasis. According to previous reports, cytologically proven malignant pleural effusion has worse prognosis than that in stage IIIC [27] but better than that in stage IV disease [28] ; therefore, this subdivision was added. Malignant pleural effusion may appear as massive pleural fluid and/or thickening of parietal pleura on CT or MRI. Transmural bowel infiltration, umbilical deposit, and parenchymal metastases in the liver and spleen or elsewhere are classified as stage IVB. Nevertheless, tumor extension from the peritoneum to the spleen or liver (stages IIIB or IIIC) should be differentiated from parenchymal metastases (stage IVB). 
Conclusions
Staging criteria of cancers of the ovary, fallopian tube, or peritoneum have been integrated according to the STIC concept. The following major changes from the previous criteria were made by the FIGO Committee on Gynecologic Oncology: Ovarian or tubal masses need no longer Ethical statement This article does not contain any studies with human participants or animals performed by any of the authors.
